Mitazalimab

• CAT Number: I041572
• CAS Number: 2055640-86-1
• Purity: ≥95%

Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment[1][2].
Mitazalimab (1 ng/mL-10 μg/mL) activates tumor associated macrophages (TAMs) in prostate tumor or ovarian tumor samples from human[2].
Mitazalimab (100 μg/mouse; i.p.; single dose) activates splenic DC and B cells in Naïve hCD40tg mice, and also results expansion of OVA-specifc CD8+ T cells in OVA-rechallenged (200 μg; i.v.; 3 times for 7 days between) mice[1].
Mitazalimab (100 and 300 μg/mouse, i.p.; on day 7, 10 and 13 post-inoculation) induces the release of proinfammatory cytokines and chemokines in the blood in MB49 (mouse bladder tumor cell line) bearing mice, and alters the composition of tumor myeloid cells, such that reduces monocytes and macrophages in favor of granulocytic cell[1].

Reference

[1]. Deronic A, et al. The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo. Cancer Immunol Immunother. 2021 Dec;70(12):3629-3642.
 [Content Brief]

[2]. Smith K E, et al. Mitazalimab, a potent CD40 agonist in combination with chemotherapy redirects and activates tumor infiltrating myeloid cells[J]. Cancer Research, 2022, 82(12_Supplement): 4155-4155.